ArticleJournal of managed care & specialty pharmacy2018

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.

Nicholas J Vogelzang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.